Towards treating female sexual dysfunction: Research reveals secrets of female sexual arousal

	Tweet

By using a novel prototype drug, researchers have discovered more about the mechanisms underlying female sexual arousal. These findings are published today in the British Journal of Pharmacology.

A team of researchers based at Pfizer’s labs in Sandwich, Kent, found that electrically stimulating the pelvic nerve increases blood flow to the genitalia, and that this effect was enhanced if they also gave a prototype drug (UK-414,495). They believe that the drug acts by blocking the breakdown of an internal chemical messenger that plays a key role in increasing blood flow during sexual arousal.

When women become aroused, blood flow increases to the vagina, labia and clitoris. This causes the organs to swell, and the vagina to relax, as well as increasing vaginal lubrication and the sensitivity of the genitalia.

Female sexual arousal disorder (FSAD) affects up to 40% of women irrespective of age. These women find that their genital organs do not respond to sexual stimulation, they find arousal difficult and this causes them to become distressed.

“Before this work, we knew surprisingly little about the processes that control all of these changes,” says the lead researcher in the project Chris Wayman. “Now we are beginning to establish the pathways involved in sexual arousal scientists may be able to find ways of helping women who would like to overcome FSAD.”

This is early stage research involving experimental studies using an animal model of sexual arousal. In it researchers stimulated the pelvic nerve and measured changes in genital organs. They believed the genital arousal occurred because stimulation of the nerve triggered the release of vasoactive intestinal peptide (VIP), a well-known neurotransmitter. VIP has only a short-lived effect, because it is soon broken down by an enzyme called Neutral Endopeptidase (NEP). The researchers believe that their prototype drug increased the arousal because it blocked NEP’s ability to break down VIP, therefore letting the VIP have a more powerful and prolonged effect increasing arousal.

The results look all the more exciting because, while the drug did increase the level of sexual arousal, it didn’t affect arousal in the absence of stimulation or the rest of the body’s cardiovascular system. This suggests that this sort of drug would have a good chance of being safe to use in women, and would only work when combined with sexual stimulation.

“While the particular chemical compound studied in this research did not prove appropriate for further development, the implications of the research could lead to the development of a product in future, although Pfizer has no current plans to develop medicines for FSAD,” added Wayman.

###

Contact: Jennifer Beal

44-124-377-0633
Wiley-Blackwell

RELATED STORIES:
Free HPV vaccine curbs new cases of genital warts   Few sexually active teens in US get HIV test: CDC   What Does the Public Really Know about HPV?   Indian state AIDS body wants to legalise gay sex   Men Report Persistent Sexual Impairment After Use of Common Hair Loss Drugs   Erectile Dysfunction Drugs Affect Other Systems, Mostly for the Better   Cardiovascular, Breast Safety Study of LibiGel In Women with Hypoactive Sexual Desire Disorder   Multi-pronged approach curbs risky sex in the HIV+   Sexual abuse - an overview   Cutaneous Application of Nanoparticles Offers Hope for Treatment of Erectile Dysfunction   Insights Into Male Fertility: New Research Shows Potential for a Male Contraceptive   Your sexual life indicative of your heart health   UK watchdog says teach sex to kids from age five   When it comes to condoms - one size does not fit all!   Most patients who have male-to-female sex-change surgery are happy, despite complications

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There is some suggestion of a link between sexual dysfunction in postmenopausal women and low circulating concentrations of testosterone.1 This underlies the development of a new transdermal testosterone patch that has recently been licensed in the UK for the treatment of women who have hypoactive sexual desire disorder HSDD following a menopause induced by surgery i.e. bilateral salpingooophorectomy and hysterectomy and who are receiving concomitant oestrogen replacement therapy. Here we discuss the diagnosis of HSDD, as well as the evidence for using transdermal testosterone patches in women in whom this diagnosis is made.

posted by Female on 04/21/2010 at 11:14 pm -08:00